Unmet Needs in Cholangiocarcinoma

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary tumours that can arise from the intrahepatic, perihilar or distal parts of the biliary tree. 1 Each anatomical tumour subtype has distinct epidemiology, molecular characteristics, prognosis and strategy for clinical management.2 Although rare (0.4–1.8 per 100,000 cases across Europe),3 the incidence of CCA, in particular intrahepatic CCA, is generally increasing worldwide.1 Diagnosis remains a challenge, due to the asymptomatic nature of the disease in its early stages and its non-specific clinical presentation.1 As a result, ~70% of patients are diagnosed with advanced disease, which compromises therapeutic options. READ MORE

Incyte-sponsored ILCA symposium:
Personalised Approaches in Cholangiocarcinoma

What is the best way to navigate the genomic diversity of cholangiocarcinoma (CCA)?

How do clinicians ensure patients with CCA receive the most appropriate treatment tailored to their individual needs?

These were the key questions addressed by four leading CCA experts, as they shared experiences and practical guidance on a precision medicine-based approach during the Incyte-sponsored educational symposium ‘Personalised Approaches in Cholangiocarcinoma’, chaired by Professor Bruno Sangro. READ MORE

FGFR2 targeting in cholangiocarcinoma